课题基金 / 基金详情

项目摘要

项目成果

Bruce R Conklin的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To achieve the goals of this PPG we will need to grow large quantities of cardiomyocytes (CMs) from mouse embryonic stem (ES) cell sources, for affinity-purification mass spectrometry (AP-MS). CM production will be scaled up from 6-well plates, to large tissue flasks and then suspension culture in a bioreactor. Although large-scale cell production is inefficient in a single lab, combining our efforts into a core laboratory will increase cell production so that the AP-MS can be achieved efficiently. SPECIFIC AIMS SUMMARY Specific Aim 1: To provide high-quality cell production capabilities for program research projects. The cell production core will enable research projects to produce large quantities of cardiac progenitors and CMs derived from engineered mouse ES cells. By expanding cells in suspension, we can attain cell production levels that are at least two orders of magnitude greater than on petri dishes. These cells will be provided to the Proteomics Core to analyze biochemical complexes that underlie cardiac differentiation. Specific Aim 2: To develop new protocols for affordable high volume CM production. Bioreactors have successfully been used to produce large amounts of mouse and human CMs in academic and industrial laboratories, but the main limitation is the cost of reagents. Typical bioreactor runs will use 100 liters of media and state-of-the-art protocols can cost >$80,000 per run. We will adapt our current protocols to bring the cost down by over 70%, allowing for the proposed experiments in a large numbers of cell lines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
  • 批准号:
    10590420
  • 项目类别:
  • 资助金额:
    $23.93万
  • 财政年份:
    2021
  • 负责人:
    Bruce R Conklin
  • 依托单位:
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
  • 批准号:
    10186371
  • 项目类别:
  • 资助金额:
    $212.63万
  • 财政年份:
    2021
  • 负责人:
    Bruce R Conklin
  • 依托单位:
Core C: Genome Engineering Core
  • 批准号:
    10245028
  • 项目类别:
  • 资助金额:
    $28.35万
  • 财政年份:
    2019
  • 负责人:
    Bruce R Conklin
  • 依托单位:
Core C: Genome Engineering Core
  • 批准号:
    10471986
  • 项目类别:
  • 资助金额:
    $28.35万
  • 财政年份:
    2019
  • 负责人:
    Bruce R Conklin
  • 依托单位:
海外基金